Market Overview

UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review

Related JNJ
Analysts See No Sweeter Deal For Volcano
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
Making Money With Charles Payne: 11/19/14 (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $97.00 to $91.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Johnson & Johnson closed on Thursday at $83.68.

Latest Ratings for JNJ

DateFirmActionFromTo
Dec 2014JP MorganMaintainsNeutral
Dec 2014JefferiesMaintainsHold
Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters